Pro Dex Inc PDEX
We take great care to ensure that the data presented and summarized in this overview for PRO DEX INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in PDEX
Top Purchases
Top Sells
About PDEX
Pro-Dex, Inc. designs, develops, and manufactures powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company was founded in 1978 and is headquartered in Irvine, California.
Insider Transactions at PDEX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 30
2025
|
Raymond E Cabillot Director |
SELL
Open market or private sale
|
Indirect |
1,100
-0.34%
|
$49,500
$45.01 P/Share
|
|
Jan 28
2025
|
Raymond E Cabillot Director |
SELL
Open market or private sale
|
Indirect |
5,381
-1.66%
|
$220,621
$41.64 P/Share
|
|
Jan 27
2025
|
Raymond E Cabillot Director |
SELL
Open market or private sale
|
Indirect |
8,077
-2.42%
|
$331,157
$41.62 P/Share
|
|
Jan 24
2025
|
Raymond E Cabillot Director |
SELL
Open market or private sale
|
Indirect |
1,436
-0.43%
|
$58,876
$41.44 P/Share
|
|
Jan 23
2025
|
Raymond E Cabillot Director |
SELL
Open market or private sale
|
Indirect |
835
-0.25%
|
$35,070
$42.0 P/Share
|
|
Jan 23
2025
|
Angelita Rebamontan Domingo Director |
BUY
Grant, award, or other acquisition
|
Direct |
15
+0.1%
|
$615
$41.11 P/Share
|
|
Jan 22
2025
|
Raymond E Cabillot Director |
SELL
Open market or private sale
|
Indirect |
2,271
-0.22%
|
$97,653
$43.18 P/Share
|
|
Jan 21
2025
|
Raymond E Cabillot Director |
SELL
Open market or private sale
|
Indirect |
6,931
-1.01%
|
$311,895
$45.39 P/Share
|
|
Jan 17
2025
|
Raymond E Cabillot Director |
SELL
Open market or private sale
|
Indirect |
6,820
-0.97%
|
$300,080
$44.79 P/Share
|
|
Jan 16
2025
|
Raymond E Cabillot Director |
SELL
Open market or private sale
|
Indirect |
1,493
-0.42%
|
$65,692
$44.24 P/Share
|
|
Jan 15
2025
|
Raymond E Cabillot Director |
SELL
Open market or private sale
|
Indirect |
1,879
-0.53%
|
$84,555
$45.18 P/Share
|
|
Jan 14
2025
|
Raymond E Cabillot Director |
SELL
Open market or private sale
|
Indirect |
1,147
-0.32%
|
$51,615
$45.18 P/Share
|
|
Jan 13
2025
|
Raymond E Cabillot Director |
SELL
Open market or private sale
|
Indirect |
3,624
-1.01%
|
$166,704
$46.66 P/Share
|
|
Jan 10
2025
|
Raymond E Cabillot Director |
SELL
Open market or private sale
|
Indirect |
1,200
-0.33%
|
$56,400
$47.76 P/Share
|
|
Nov 22
2024
|
Angelita Rebamontan Domingo Director |
SELL
Payment of exercise price or tax liability
|
Direct |
3,198
-18.08%
|
$147,108
$46.75 P/Share
|
|
Nov 22
2024
|
Angelita Rebamontan Domingo Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,250
+19.37%
|
$114,750
$27.5 P/Share
|
|
Nov 20
2024
|
Nicholas John Swenson Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,000
+1.02%
|
-
|
|
Nov 20
2024
|
David Hovda Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,000
+23.26%
|
$1,000
$1.0 P/Share
|
|
Nov 20
2024
|
Katrina Marie Kramer Philp Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,000
+50.0%
|
-
|
|
Nov 20
2024
|
Richard Lee Van Kirk Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,000
+0.99%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 40.5K shares |
|---|---|
| Exercise of conversion of derivative security | 4.25K shares |
| Payment of exercise price or tax liability | 5.24K shares |
| Payment of exercise price or tax liability | 9.73K shares |
|---|---|
| Open market or private sale | 45.8K shares |